Natera Inc (NASDAQ:NTRA) COO Steven Leonard Chapman sold 45,000 shares of Natera stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total transaction of $1,132,200.00. Following the sale, the chief operating officer now owns 16,628 shares of the company’s stock, valued at $418,360.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

  • On Monday, June 25th, Steven Leonard Chapman sold 86,919 shares of Natera stock. The shares were sold at an average price of $18.00, for a total transaction of $1,564,542.00.

Shares of NTRA stock opened at $24.42 on Friday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of -3.32. The company has a market capitalization of $1.52 billion, a P/E ratio of -10.18 and a beta of 2.21. Natera Inc has a fifty-two week low of $8.60 and a fifty-two week high of $29.62.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.55). The firm had revenue of $63.07 million during the quarter, compared to analysts’ expectations of $61.71 million. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.55) earnings per share. research analysts predict that Natera Inc will post -2.05 EPS for the current year.

A number of institutional investors have recently modified their holdings of the stock. Sofinnova Ventures Inc purchased a new position in Natera in the first quarter worth approximately $28,742,000. Jennison Associates LLC lifted its stake in Natera by 1.4% in the second quarter. Jennison Associates LLC now owns 2,617,623 shares of the medical research company’s stock worth $49,264,000 after acquiring an additional 36,876 shares during the last quarter. BlackRock Inc. lifted its stake in Natera by 19.4% in the second quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock worth $39,274,000 after acquiring an additional 338,766 shares during the last quarter. Fred Alger Management Inc. purchased a new position in Natera in the second quarter worth approximately $33,271,000. Finally, Macquarie Group Ltd. lifted its stake in Natera by 9.0% in the second quarter. Macquarie Group Ltd. now owns 1,714,886 shares of the medical research company’s stock worth $32,274,000 after acquiring an additional 141,278 shares during the last quarter. Institutional investors own 66.31% of the company’s stock.

A number of research analysts recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Natera from $17.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, June 28th. BidaskClub cut shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. Craig Hallum set a $23.00 price objective on shares of Natera and gave the company a “positive” rating in a report on Thursday, June 28th. ValuEngine upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a report on Friday, June 22nd. Finally, Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Natera has a consensus rating of “Buy” and an average target price of $23.14.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: What is Compound Annual Growth Rate (CAGR)?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.